PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of headpainSpringerOpen.comSubmit OnlineRegisterThis journalThis article
 
J Headache Pain. 2010 December; 11(6): 477–483.
Published online 2010 October 27. doi:  10.1007/s10194-010-0263-7
PMCID: PMC2995862

A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) that act as cyclo-oxygenase (COX) inhibitors are commonly used in the treatment of a range of headache disorders, although their mechanism of action is unclear. Indomethacin is of particular interest given its very special effect in some primary headaches. Here the in vivo technique of intravital microscopy in rats has been utilised as a model of trigeminovascular nociception to study the potential mechanism of action of indomethacin. Dural vascular changes were produced using electrical (neurogenic) dural vasodilation (NDV), calcitonin gene-related peptide (CGRP) induced dural vasodilation and nitric oxide (NO) induced dural vasodilation using NO donors. In each of these settings the effect of intravenously administered indomethacin (5 mg kg−1), naproxen (30 mg kg−1) and ibuprofen (30 mg kg−1) was tested. All of the tested drugs significantly inhibited NDV (between 30 and 52%). Whilst none of them was able to inhibit CGRP-induced dural vasodilation, only indomethacin reduced NO induced dural vasodilation (35 ± 7%, 10 min post administration). We conclude NSAIDs inhibit release of CGRP after NDV without an effect on CGRP directly. Further we describe a differentiating effect of indomethacin inhibiting nitric oxide induced dural vasodilation that is potentially relevant to understanding its unique action in disorders such as paroxysmal hemicrania and hemicrania continua.

Keywords: Trigeminal, NSAID, COX, Headache, Vasodilation, Rat

Full Text

The Full Text of this article is available as a PDF (219K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257–270. doi: 10.1056/NEJMra010917. [PubMed] [Cross Ref]
2. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci. 1994;714:136–142. doi: 10.1111/j.1749-6632.1994.tb12037.x. [PubMed] [Cross Ref]
3. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs) Am J Med. 1999;107:11S–16S. doi: 10.1016/S0002-9343(99)00363-0. [PubMed] [Cross Ref]
4. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache. 1993;33:541–550. doi: 10.1111/j.1526-4610.1993.hed3310541.x. [PubMed] [Cross Ref]
5. Ellrich J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain. 1999;81:7–14. doi: 10.1016/S0304-3959(98)00267-X. [PubMed] [Cross Ref]
6. Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007;148:573–583. doi: 10.1016/j.neuroscience.2007.04.064. [PMC free article] [PubMed] [Cross Ref]
7. Headache Classification Committee of The International Headache Society The International Classification of Headache Disorders (second edition) Cephalalgia. 2004;24(Suppl 1):1–160. [PubMed]
8. Akerman S, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide induced dilation of dural meningeal vessels. Eur J Pharmacol. 2002;452:223–228. doi: 10.1016/S0014-2999(02)02307-5. [PubMed] [Cross Ref]
9. Yang GY, Lee MK, Bae YC, Ahn DK. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:589–595. doi: 10.1016/j.pnpbp.2009.02.010. [PubMed] [Cross Ref]
10. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339(Pt 3):607–614. doi: 10.1042/0264-6021:3390607. [PubMed] [Cross Ref]
11. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 1993;90:11693–11697. doi: 10.1073/pnas.90.24.11693. [PubMed] [Cross Ref]
12. Noreen Y, Ringbom T, Perera P, Danielson H, Bohlin L. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998;61:2–7. doi: 10.1021/np970343j. [PubMed] [Cross Ref]
13. Andreou AP, Summ O, Charbit AR, Romero Reyes M, Goadsby PJ. Animal models of headache––from bedside to bench and back to beside. Exp Rev Neurother. 2010;10:389–411. doi: 10.1586/ern.10.16. [PubMed] [Cross Ref]
14. Gupta S, Bhatt DK, Boni LJ, Olesen J (2010) Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia [PubMed]
15. Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, et al. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain. 2008;9:151–157. doi: 10.1007/s10194-008-0036-8. [PubMed] [Cross Ref]
16. Iversen HK, Olesen J. Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide. Cephalalgia. 1994;14:437–442. doi: 10.1046/j.1468-2982.1994.1406437.x. [PubMed] [Cross Ref]
17. Akerman S, Goadsby PJ. The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005;314:162–169. doi: 10.1124/jpet.105.083139. [PubMed] [Cross Ref]
18. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonise neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;137:62–68. doi: 10.1038/sj.bjp.0704842. [PMC free article] [PubMed] [Cross Ref]
19. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat- intravital microscope studies. Cephalalgia. 1997;17:525–531. doi: 10.1046/j.1468-2982.1997.1704525.x. [PubMed] [Cross Ref]
20. Omogbai EK, Ozolua RI, Idaewor PE, Isah AO. Some studies on the rodenticidal action of indomethacin. Drug Chem Toxicol. 1999;22:629–642. doi: 10.3109/01480549908993172. [PubMed] [Cross Ref]
21. Wagerle LC, Degiulio PA. Indomethacin-sensitive CO2 reactivity of cerebral arterioles is restored by vasodilator prostaglandin. Am J Physiol. 1994;266:H1332–H1338. [PubMed]
22. Busija DW, Leffler CW, Wagerle LC. Mono-l-Arginine containing compounds dilate piglet pial arterioles via an endothelium-derived relaxing factor like substance. Circ Res. 1990;67:1374–1380. [PubMed]
23. Akerman S, Kaube H, Goadsby PJ. Vanilloid receptor 1 (VR1) evoked CGRP release plays a minor role in causing dural vessel dilation via the trigeminovascular system. Cephalalgia. 2002;22:572.
24. Edwards RM, Stack EJ, Trizna W. Calcitonin gene-related peptide stimulates adenylate cyclase and relaxes intracerebral arterioles. J Pharmacol Exp Ther. 1991;257:1020–1024. [PubMed]
25. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142. [PubMed]
26. Messlinger K, Suzuki A, Pawlak M, Zehnter A, Schmidt RF. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br J Pharmacol. 2000;129:1397–1404. doi: 10.1038/sj.bjp.0703220. [PMC free article] [PubMed] [Cross Ref]
27. Strecker T, Dux M, Messlinger K. Increase in meningeal blood flow by nitric oxide-interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia. 2002;22:233–241. doi: 10.1046/j.1468-2982.2002.00356.x. [PubMed] [Cross Ref]
28. Iversen H. Human migraine models. Cephalalgia. 2001;21:781–785. doi: 10.1046/j.1468-2982.2001.00250.x. [PubMed] [Cross Ref]
29. Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004;24:110–119. doi: 10.1111/j.1468-2982.2004.00639.x. [PubMed] [Cross Ref]
30. Ekbom K. Nitroglycerin as a provocative agent in cluster headache. Arch Neurol. 1968;19:487–493. [PubMed]
31. Giffin NJ. Paroxysmal hemicrania triggered by GTN. Cephalalgia. 2007;27:953–954. doi: 10.1111/j.1468-2982.2007.01350.x. [PubMed] [Cross Ref]
32. Schoonman GG, Grond J, Kortmann C, Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is not associated with cerebral or meningeal vasodilatation––a 3T magnetic resonance angiography study. Brain. 2008;131:2192–2200. doi: 10.1093/brain/awn094. [PubMed] [Cross Ref]
33. Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide production in rat microglia in vitro. Int J Immunopharmacol. 1999;21:219–225. doi: 10.1016/S0192-0561(98)00084-8. [PubMed] [Cross Ref]
34. Goadsby PJ, Uddman R, Edvinsson L. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res. 1996;707:110–118. doi: 10.1016/0006-8993(95)01206-0. [PubMed] [Cross Ref]
35. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19:115–127. doi: 10.1097/00004647-199902000-00001. [PubMed] [Cross Ref]
36. Capuano A, Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain. 2009;5:43. doi: 10.1186/1744-8069-5-43. [PMC free article] [PubMed] [Cross Ref]
37. Varga H, Pardutz A, Vamos E, Plangar I, Egyud E, Tajti J, et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache. 2007;47:1319–1325. doi: 10.1111/j.1526-4610.2006.00721.x. [PubMed] [Cross Ref]
38. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112:440–449. [PMC free article] [PubMed]
39. Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin. Pharm Res. 2006;23:873–881. doi: 10.1007/s11095-006-9905-5. [PubMed] [Cross Ref]
40. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212–216. doi: 10.1038/35102591. [PubMed] [Cross Ref]

Articles from The Journal of Headache and Pain are provided here courtesy of Springer